Inhibition of ERK1/2, p38 and JNK kinases may be efficacious for the treatment of AD through attenuation of Aβ-induced neurotoxicity via activation of the Erk1/2, p38 and JNK pathways 158, 159. This evidence concerns the gene MAPK3 and Alzheimer disease.